Le médicament qui devait sauver l’Afrique
by Guillaume Lachenal
La Découverte, 2014, 250 pages.
Guillaume Lachenal’s Le médicament qui devait sauver l’Afrique – the English-language title provided by the publishing house is The hidden history of the medicine meant to save Africa – is devoted to a pharmaceutical scandal in colonial Africa that remains absent from the official history. …
Ian Harper, Professor of Anthropology, Health, and Development at the University of Edinburgh, talks to Alice Street about his book Development and Public Health in the Himalaya: Reflections on Healing in Contemporary Nepal.
AS: Ian, maybe you can tell us a little bit about your history as a medical practitioner, and how you came to work in Nepal.
Racial Prescriptions: Pharmaceuticals, Difference, and the Politics of Life
by Jonathan Xavier Inda
Ashgate, 2014, 148 pages.
Racial Prescriptions provides an eloquent and theoretically-engaged account of the story of BiDil, a pharmaceutical that has become an iconic case for scholars of race in science and medicine. When BiDil was approved by the U.S. Food and Drug Administration (FDA) in …
Speculative Markets: Drug Circuits and Derivative Lives in Nigeria
by Kristin Peterson
Duke University Press, 2014, 264 pages.
In her remarkable book, Speculative Markets: Drug Circuits and Derivative Lives in Nigeria, Kristin Peterson sets out to explore and resituate the pharmaceutical industry, and pharmaceutical markets, in Nigeria. The outcome is a highly-detailed, carefully analyzed and enlightening piece of …
Welcome to our inaugural “Book Forum.” Our aim is simple: to promote lively exchange between a group of scholars and an author, allowing for experimental and inventive engagements that are not so much about evaluation but rather draw on concepts and shared commitments. It’s probably worth noting that Somatosphere will continue to feature book reviews, which have been a mainstay …
Drugs for Life: How Pharmaceutical Companies Define Our Health
by Joseph Dumit
Duke University Press, 2012. pp. 280.
Since the 1970s, scholarly work on pharmaceuticals has long engaged a number of concerns, debates and controversies: the socialities and politics of consumption, the commercialization of the life sciences, and restricted access to life-saving medicines as a result of global patent and …